Medicine man is still around, reading and marking posts. The 18...

Medicine man is still around, reading and marking posts. The 18 cents off market purchase last July marked the beginning of an accumulation period with new substantial holder concluding business with the 43 mil shares off market trade at 14 cents in February ( full amount 200 mil shares) Broker algorithms of sweeps on volume paired with creating consecutive lows on lower volume to drive price down to 6 cents, cleverly taking advantage of a derailing macro market and biotech break in in the US. Once that price level was reached we can expect news cycle to begin, analysts and broker reports to support the algorithm in reverse to accumulate on the way up to reach 12 to 15 cents be years end. All this to mirror Goldman Sachs in 2006 to 2008 , making money on the way up and doing the same on the way down. The focus on concentrating on the domestic market prior to re-engaging with the US to license out parts of the platform necessitated a price destruction to enable broker caused accumulation for its clients which will drive the price on tox data and CNS candidate news , expected this quarter. The biotech game is a long game and last year’s conditions offered by potential US partners equalled a sell out for short term gains. The longer game caused a price decay in the interim but should provide more compelling basis for a partnership on solid data footing. This quarter marks the turnaround and early next year I expect steep price increases, all IMO